Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.09USD
4:09pm GMT
Change (% chg)

$-0.28 (-3.40%)
Prev Close
$8.38
Open
$8.45
Day's High
$8.66
Day's Low
$8.06
Volume
39,503
Avg. Vol
73,517
52-wk High
$9.22
52-wk Low
$3.76

Latest Key Developments (Source: Significant Developments)

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article

Adaptimmune Therapeutics reports Q2 loss per share $0.05
Monday, 8 Aug 2016 

Adaptimmune Therapeutics Plc : Adaptimmune reports second quarter 2016 financial results . Q2 revenue view $3.6 million -- Thomson Reuters I/B/E/S . Qtrly loss per share $0.05 . Adaptimmune is reiterating its guidance for 2016 .Q2 revenue $300,000 versus $2.8 million.  Full Article

Adaptimmune Q2 net loss per diluted ordinary share $0.05
Monday, 8 Aug 2016 

Adaptimmune Therapeutics Plc : Q2 revenue $300,000 versus $2.8 million . Adaptimmune reports second quarter 2016 financial results . Q2 revenue view $3.6 million -- Thomson Reuters I/B/E/S . Reiterating its FY 2016 guidance . Qtrly net loss per diluted ordinary share $0.05 .Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Adaptimmune announces partial clinical hold of planned pivotal study
Wednesday, 3 Aug 2016 

Adaptimmune Therapeutics Plc : Adaptimmune announces partial clinical hold of planned pivotal study of ny-eso spear® t-cell therapy in myxoid round cell liposarcoma . Trial is not yet active at any investigational sites, and has not recruited any patients . Notification of partial clinical hold does not apply to any other adaptimmune study . Fda notification is not based on safety concerns . Fda requested additional cmc information and answers to certain trial design questions prior to trial start .Notice from u.s. Fda that partial clinical hold placed on planned pivotal study of ny-eso spear t-cell therapy.  Full Article

Adaptimmune gets priority medicines regulatory support for its Spear T-cell therapy
Thursday, 28 Jul 2016 

Adaptimmune Therapeutics Plc :Adaptimmune receives access to priority medicines (PRIME) regulatory support for its Spear T-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma.  Full Article

Adaptimmune Therapeutics receives positive opinion
Monday, 20 Jun 2016 

Adaptimmune Therapeutics Plc : Adaptimmune receives positive opinion for orphan drug designation in the European Union for spear t-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma .Says expects to initiate pivotal studies in synovial sarcoma in 4Q16/1Q17.  Full Article

Adaptimmune Therapeutics says Jonathan Knowles resigned from board
Tuesday, 24 May 2016 

Adaptimmune Therapeutics Plc : Says Jonathan Knowles resigned from board . Says David Mott to succeed Knowles, mott now appointed vice chairman of the board .Says Knowles will step down on Dec, 2016, and will be succeeded as chairman by David Mott.  Full Article

Adaptimmune Q1 revenue $2.9 million versus $2.7 million
Thursday, 12 May 2016 

Adaptimmune Therapeutics Plc : Adaptimmune reports first quarter 2016 financial results .Q1 revenue $2.9 million versus $2.7 million.  Full Article

Adaptimmune Q1 revenue $2.9 million versus $2.7 million
Thursday, 12 May 2016 

Adaptimmune Therapeutics Plc : Company is reiterating its cash burn guidance . Adaptimmune therapeutics plc qtrly loss per share $0.04 per ordinary share . Q1 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S . Adaptimmune reports first quarter 2016 financial results .Q1 revenue $2.9 million versus $2.7 million.  Full Article

Adaptimmune Therapeutics plc says FDA grants breakthrough therapy designation for its T-cell therapy
Tuesday, 9 Feb 2016 

Adaptimmune Therapeutics plc:U.S. food and drug administration grants breakthrough therapy designation for adaptimmune's affinity enhanced t-cell therapy targeting ny-eso in synovial sarcoma.Says breakthrough therapy designation was based on the results of a phase i/ii trial in patients.  Full Article

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates